Rest of the World

Business environment
Strategy, goals & performance measurement
Resources, skills & capabilities
Financial review
Geographical review
Therapy area review
Other businesses
Environmental sustainability
In the global community
Risk
Business organisation & corporate governance
Reported, constant exchange rate & core financial measures

Sales in the rest of the world performed strongly in 2008, up 5% (+12% reported) to $16,816 million (2007: $15,048 million). Key products (Arimidex, Crestor, Nexium, Seroquel and Symbicort) delivered a strong performance, up 14% (+20% reported) with sales of $7,413 million (2007: $6,189 million). Latin America, the Middle East and Africa and Asia Pacific regions delivered particularly strong sales, up 13% (+19% reported) with sales of $5,858 million (2007: $4,906 million).